A $37 million Series A financing round was closed by clinical-stage biotechnology business AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. which operates in both China and the United States.
InnoPinnacle Fund, an existing investor, led the round. New investors Yuanbio Venture Capital, Qiming Venture Partners, Hankang Capital, and Genesis Capital also participated.
The lead product candidate for AusperBio, AHB-137, will continue to receive clinical development support thanks to the financing’s profits. Furthermore, the money will be used to develop its product pipelines and its exclusive Med-OligoTM technology platform.
AusperBio is a clinical-stage biopharmaceutical business headed by co-founder and CEO Dr. Guofeng Cheng. The company’s mission is to advance targeted oligonucleotide therapeutics in order to achieve a functional cure for chronic hepatitis B (CHB) infection.
Read also- China-Based Hongshan Secures $2.5 Billion in Funding
Through innovative insights into ASO design, the company’s unique Med-OligoTM ASO platform has been demonstrated to significantly improve the available ASO therapies.
The modular Med-OligoTM Platform, when combined with effective targeted delivery conjugation technologies, enables ASO therapies to treat a wide range of diseases, such as immune system disorders, metabolic disorders, viral infections, and genetic abnormalities.
Developed using AusperBio’s own Med-OligoTM ASO technology platform, AHB-137 is a new unconjugated antisense oligonucleotide (ASO) intended to treat chronic hepatitis B and provide a functional cure. At the 2023 and 2024 EASLTM conferences, respectively, its highly persuasive preclinical and Phase 1 clinical data were presented.
Read also- Singapore-Based Partior Secures $60 Million in Series B Round Funding
A Phase 1b trial is currently being conducted on this unique dual-mechanism ASO in several international research sites, while a Phase 2 trial is being conducted concurrently in China. With the help of a worldwide development approach, AHB-137 is making great progress towards curing HBV.
About AusperBio
AusperBio is a Phase II biopharmaceutical firm developing curative HBV therapy and oligonucleotide therapies. Through our Med-Oligo™ ASO platform and targeted delivery.
